TAVR and Anticoagulation: What Should We Do?

Transcatheter aortic valve replacement (TAVR) has consolidated as a valid strategy for certain groups of patients. However, approximately one third of those who require this therapy are being treated with anticoagulants (AC).

Anticoagulación y TAVI

Even though the current guidelines suggest interrupting anticoagulation to reduce bleeding risk, the available evidence has not yet fully elucidated this recommendation. 

This analysis of POPular PAUSE TAVI, included 858 patients treated with anticoagulants undergoing TAVR. 431 (50.2%) of these patients continued with AC (AC+), while the rest stopped AC and continued after procedure, according to treating physician criteria (AC-). 

The primary outcome was a composite of cardiovascular death, stroke, infarction, vascular complications or major bleeding within 30 days after procedure. 

Baseline group characteristics were similar: mean age 81, one third women, 3.8 STS Score, atrial fibrillation in 96% of cases, 4.5 CHA2DS2-VASc Score, 78% were hypertensive, 30% diabetic, 33% had a history of CABG, 15% had infarction history, 11% stroke, 10% TIA, 13% COPD, there was kidney function deterioration in 50% and prior TAVR in 7%.

Read also: RODIN-CUT: Successive Cutting Balloon Technique in Calcified Lesions.

There were no differences in primary end point, with 16.5% incidence in AC+ patients vs 14.8% in AC- (risk difference: 1.7 percentual points, CI 95%: −3.1 to 6.6; P = 0.18 for non-inferiority). Neither were there differences in cardiovascular mortality, all cause stroke, infarction, major bleeding or major vascular complications. 

Conclusion

In TAVR patients, periprocedural anticoagulation was shown non-inferior vs. AC interruption as regards the incidence of the combined end point of cardiovascular death, stroke, infarction, major vascular complications and major bleeding at 30 days. 

Original Title: Continuation versus Interruption of Oral Anticoagulation during TAVI. POPular PAUSE TAVI Trial.

Reference: D.J. van Ginkel, et al. N Engl J Med 2025;392:438-49. DOI: 10.1056/NEJMoa2407794.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Carlos Fava
Dr. Carlos Fava
Member of the Editorial Board of solaci.org

More articles by this author

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

Embolization of Left Atrial Appendage Closure Devices: Predictors, Prevention, and Management Strategies

Atrial fibrillation is associated with an increased risk of stroke and, in patients with contraindications to anticoagulation, percutaneous left atrial appendage closure represents an...

Drugs for the Treatment of No-Reflow During PCI

The no-reflow phenomenon is one of the most frustrating complications of primary angioplasty (pPCI), reflecting persistent microvascular damage that, in the mid- to long-term,...

Coronary revascularization before TAVI: prior PCI or conservative management?

The coexistence of coronary artery disease (CAD) in patients with severe aortic stenosis undergoing TAVI is common, with a reported prevalence ranging from 30%...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...